Fig. 2

Long-term clinical remission for patients in TDM and non-TDM cohorts. (A) clinical remission for patients achieved clinical remission at baseline. (B) Clinical remission for patients reached endoscopic response at baseline. (C) Clinical remission for patients with mucosal healing at baseline. TDM group, patients received optimized ustekinumab maintenance treatment guided by TDM; non-TDM group, patients received routinely subcutaneous ustekinumab maintenance treatment.